Thomas P. Loughran Jr.

Thomas P. Loughran, Jr. is an American physician-scientist who specializes in cancer research and treatment. He became director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine at the University of Virginia on August 15, 2013.[1] Between 2003 and 2013, Loughran served as the founding director of the Penn State Hershey Cancer Institute and professor of medicine at the Penn State College of Medicine. His previous appointments included program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center and chief of hematology at the Syracuse Veteran’s Affairs Medical Center in Syracuse, N.Y.[2] Loughran completed his fellowship in medical oncology in 1985 at the Fred Hutchinson Cancer Research Center in Seattle, Washington under direction of Nobel Laureate E. Donnall Thomas. He remained on faculty there for seven years. Loughran earned his medical degree from Hahnemann Medical School in Philadelphia in 1979.[1]

Thomas P. Loughran, Jr.
Thomas P. Loughran, Jr.
NationalityAmerican
Alma materHahnemann Medical School
Scientific career
Fields
Institutions

LGL leukemia research

Loughran's primary research interest is large granular lymphocyte leukemia (LGL), a hematologic malignancy he discovered in the mid-1980s.[3] He is considered the international expert on this form of leukemia.[4] He has received continuous federal grant support for the past 26 years and currently is the principal investigator on two R01 grants and a P01 grant from the National Cancer Institute, as well as a translational research grant from the Leukemia & Lymphoma Society. Loughran has published numerous articles in high impact peer-reviewed journals including The New England Journal of Medicine,[5] Annals of Internal Medicine,[6] The Lancet,[7] Journal of Clinical Investigation,[8] Journal of Clinical Oncology,[9] and Blood.[10]

Loughran holds American Board certifications in internal medicine and medical oncology. In his clinical practice, he treats patients with bone marrow disorders and leukemia.[11]

References
  1. "Thomas P. Loughran Jr., MD, appointed director of UVA Cancer Center". University of Virginia Health System Official Website. Retrieved 2013-11-21.
  2. "Observe, lead, discover". Ursinus Magazine Fall 2013. Retrieved 2013-11-21.
  3. "Hershey doctor's pioneering work with rare leukemia offers hope to patients worldwide". The Patriot-News. Retrieved 2013-11-25.
  4. https://cancer.uvahealth.com/LGLLeBookNew.pdf
  5. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S. "Somatic STAT3 mutations in large granular lymphocytic leukemia". New England Journal of Medicine. 366: 1905–13. doi:10.1056/NEJMoa1114885. PMC 3693860. PMID 22591296.CS1 maint: multiple names: authors list (link)
  6. Wallis WJ, Loughran TP Jr, Kadin ME, Clark EA, Starkebaum GA. "Polyarthritis and neutropenia associated with circulating large granular lymphocytes". Annals of Internal Medicine. 103: 357–62. doi:10.7326/0003-4819-103-3-357. PMID 4026084.CS1 maint: multiple names: authors list (link)
  7. Starkebaum G, Loughran TP Jr, Kalyanaraman VS, Kadin ME, Kidd PG, Singer JW, Ruscetti FW. "Serum reactivity to human T-cell leukaemia/lymphoma virus type I proteins in patients with large granular lymphocytic leukaemia". Lancet. 1: 596–9. doi:10.1016/s0140-6736(87)90236-4. PMID 2881134.CS1 maint: multiple names: authors list (link)
  8. Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G Jr, Benson DM, Loughran TP Jr, Tridandapani S, Caligiuri MA. "NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human". Journal of Clinical Investigation. 121: 1456–70. doi:10.1172/JCI43242. PMC 3069763. PMID 21364281.CS1 maint: multiple names: authors list (link)
  9. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP Jr, Maciejewski JP. "Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes". Journal of Clinical Oncology. 28: 2253–8. doi:10.1200/JCO.2009.26.0745. PMC 2860439. PMID 20354132.CS1 maint: multiple names: authors list (link)
  10. Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagström S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP Jr, Maciejewski JP. "STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients". Blood. 122: 2453–9. doi:10.1182/blood-2013-04-494930. PMC 3790512. PMID 23926297.CS1 maint: multiple names: authors list (link)
  11. "Thomas Loughran, MD Cancer Center". University of Virginia Health System Official Website. Retrieved 2013-11-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.